Kang Howson‐Jan

1.7k total citations
33 papers, 666 citations indexed

About

Kang Howson‐Jan is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Kang Howson‐Jan has authored 33 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 15 papers in Genetics and 10 papers in Oncology. Recurrent topics in Kang Howson‐Jan's work include Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Kang Howson‐Jan is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Hematopoietic Stem Cell Transplantation (7 papers). Kang Howson‐Jan collaborates with scholars based in Canada, United States and Japan. Kang Howson‐Jan's co-authors include Mickie Bhatia, Michael Keeney, D. Robert Sutherland, David Allan, Axel A. Fauser, Alan Brox, Keyue Ding, Stephen Couban, Andrew R. Belch and Ralph M. Meyer and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.

In The Last Decade

Kang Howson‐Jan

32 papers receiving 653 citations

Peers

Countries citing papers authored by Kang Howson‐Jan

Since Specialization

Citations

This map shows the geographic impact of Kang Howson‐Jan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang Howson‐Jan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang Howson‐Jan more than expected).

Fields of papers citing papers by Kang Howson‐Jan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kang Howson‐Jan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang Howson‐Jan. The network helps show where Kang Howson‐Jan may publish in the future.

Co-authorship network of co-authors of Kang Howson‐Jan

This figure shows the co-authorship network connecting the top 25 collaborators of Kang Howson‐Jan. A scholar is included among the top collaborators of Kang Howson‐Jan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kang Howson‐Jan. Kang Howson‐Jan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely? 2021 ·International Journal of Laboratory Hematology ·Eri Kawata, Benjamin D. Hedley, Benjamin Chin‐Yee, Anargyros Xenocostas, Alejandro Lazo‐Langner, Cyrus C. Hsia, Kang Howson‐Jan, Ping Yang, Michael A. Levy, (unknown), (unknown), Christopher J. Howlett, Hanxin Lin, Mike Kadour, Bekim Sadiković, Ian Chin‐Yee	2
2	Effect of Levofloxacin Prophylaxis on Rates of Febrile Neutropenia in Patients Receiving DA-EPOCH-R Chemotherapy for Aggressive Lymphomas 2021 ·Blood ·(unknown), Mina Dehghani, Selay Lam, (unknown), (unknown), Kang Howson‐Jan, Joy Mangel	1
3	Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome 2020 ·British Journal of Haematology ·Eri Kawata, Alejandro Lazo‐Langner, Anargyros Xenocostas, Cyrus C. Hsia, Kang Howson‐Jan, (unknown), (unknown), Ping Yang, (unknown), Michael A. Levy, Christopher J. Howlett, Alan Stuart, Jennifer Kerkhof, (unknown), Hanxin Lin, Bekim Sadiković, Ian Chin‐Yee	8
4	The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas 2019 ·Blood ·(unknown), (unknown), Joy Mangel, Selay Lam, Kang Howson‐Jan, (unknown)	2
5	Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia 2018 ·Blood ·(unknown), Rosanne St. Bernard, Alejandro Lazo‐Langner, Anargyros Xenocostas, Joy Mangel, Kang Howson‐Jan, Selay Lam, Cyrus C. Hsia	3
6	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^* 2016 ·Leukemia & lymphoma ·Tara Baetz, Bingshu E. Chen, Stephen Couban, C. Tom Kouroukis, Rena Buckstein, John Kuruvilla, Kang Howson‐Jan, David Szwajcer, Massimo Federico, Ralph M. Meyer, Marina Djurfeldt, Annette E. Hay, Lois E. Shepherd, Michael Crump	8
7	Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia 2014 ·Current Oncology ·David Sanford, (unknown), Alejandro Lazo‐Langner, Anargyros Xenocostas, Ian Chin‐Yee, Kang Howson‐Jan, Cyrus C. Hsia	19
8	Predictors of unsuccessful mobilization with granulocyte colony‐stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation 2013 ·Journal of Clinical Apheresis ·Signy Chow, Alejandro Lazo‐Langner, (unknown), Kang Howson‐Jan, Anargyros Xenocostas	7
9	Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level 2010 ·Blood ·Joseph Brandwein, Jeannine Kassis, Brian Leber, Kang Howson‐Jan, Mark D. Minden, Kim Greaves, Jean‐François Pouliot	2
10	Hodgkin lymphoma with cutaneous involvement 2009 ·Dermatology Online Journal ·Cyrus C. Hsia, Kang Howson‐Jan, Kamilia Rizkalla	12
11	A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over 2008 ·Leukemia ·Joseph Brandwein, Brian Leber, Kang Howson‐Jan, Aaron D. Schimmer, Andre C. Schuh, Vikas Gupta, Karen Yee, James R. Wright, Malcolm J. Moore, (unknown), Mark D. Minden, (unknown)	10
12	Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF 2008 ·Bone Marrow Transplantation ·Cyrus C. Hsia, Michael Linenberger, Kang Howson‐Jan, Joy Mangel, Ian Chin‐Yee, SJ Collins, Anargyros Xenocostas	8
13	An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting 2004 ·Biology of Blood and Marrow Transplantation ·Christopher Bredeson, Chantal S. Leger, Stephen Couban, David Simpson, Lothar Huebsch, Irwin Walker, Tsiporah B. Shore, Kang Howson‐Jan, Tony Panzarella, Hans A. Messner, Michael J. Barnett, Jeff H. Lipton	46
14	High‐Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre 2004 ·Sarcoma ·Sébastien J. Hotte, Anne Marie Smith, Vivien Bramwell, Kang Howson‐Jan	3
15	Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma 2004 ·Cancer ·Michael Crump, Tara Baetz, Stephen Couban, Andrew R. Belch, Deborah Marcellus, Kang Howson‐Jan, Kevin Imrie, Robert E. Myers, Grenfell Adams, Keyue Ding, Nancy Paul, Lois E. Shepherd, José Iglesias, Ralph M. Meyer	94
16	Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation 2002 ·Bone Marrow Transplantation ·David Allan, Michael Keeney, Kang Howson‐Jan, (unknown), (unknown), Mickie Bhatia, D. Robert Sutherland, (unknown)	185
17	Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets 2002 ·Bone Marrow Transplantation ·(unknown), Michael Keeney, (unknown), Andrew R. Belch, (unknown), Stephen Couban, Kang Howson‐Jan, Morel Rubinger, (unknown), Robert Sutherland, (unknown), Mickie Bhatia, Ronan Foley	8
18	Suppression of Myelopoiesis and Myeloid Leukemia Cell Line Proliferation by a Novel Bone Marrow-Derived Factor, Reptimed 1997 ·Cellular Immunology ·Rodney P. DeKoter, (unknown), Wai Gin Fong, (unknown), (unknown), Kang Howson‐Jan, Sharwan K. Singhal	3
19	IN UTERO ENGRAFTMENT OF FULLY H-2-INCOMPATIBLE VERSUS CONGENIC ADULT BONE MARROW TRANSFERRED INTO NONANEMIC OR ANEMIC MURINE FETAL RECIPIENTS 1993 ·Transplantation ·Kang Howson‐Jan, Yousif Matloub, Daniel A. Vallera, Bruce R. Blazar	32
20	Treatment of idiopathic thrombocytopenic purpura with ascorbate 1988 ·British Journal of Haematology ·Alan Brox, Kang Howson‐Jan, Axel A. Fauser	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact